Wound healing property of a gel prepared by the combination of Pseudomonas aeruginosa alginate and Alhagi maurorum aqueous extract in rats

Dermatologic Therapy, Volume 0, Issue ja, -Not available-.


https://ift.tt/2qgfwLL

A liposome‐based formulation containing equol, dihomo‐γ‐linolenic acid (DGLA), and propionyl‐L‐carnitine to prevent and treat hair loss: a prospective investigation

Dermatologic Therapy, Volume 0, Issue ja, -Not available-.


https://ift.tt/2Q7bCQv

Does chronic immunosuppressive therapy for autoimmune disease influence the risk of developing active tuberculosis?

Dermatologic Therapy, Volume 0, Issue ja, -Not available-.


https://ift.tt/2qjxj4D

Immune and Genetic Features of the Chromosome 22q11.2 Deletion (DiGeorge Syndrome)

Abstract

Purpose of Review

This review provides an update on the progress in identifying the range of immunological dysfunction seen in DiGeorge syndrome and on more recent diagnostic and treatment approaches.

Recent Findings

Clinically, the associated thymic hypoplasia/aplasia is well known and can have profound effects on T cell function. Further, the humoral arm of the immune system can be affected, with hypogammaglobulinemia and poor vaccine-specific antibody response. Additionally, genetic testing utilizing chromosomal microarray demonstrates a small but significant number of 22q11 deletions that are not detectable by standard FISH testing. The recent addition of a TREC assay to newborn screening can identify a subset of infants whose severe immune defects may result from 22q11 deletion. This initial presentation now also places the immunologist in the role of "first responder" with regard to diagnosis and management of these patients.

Summary

DiGeorge syndrome reflects a clinical phenotype now recognized by its underlying genetic diagnosis, chromosome 22q11.2 deletion syndrome, which is associated with multisystem involvement and variable immune defects among patients. Updated genetic and molecular techniques now allow for earlier identification of immune defects and confirmatory diagnoses, in this disorder with life-long clinical issues.

https://ift.tt/2zcSXLT

Innovation in Food Challenge Tests for Food Allergy

Abstract

Purpose of Review

This review incorporates findings from studies of oral food challenges (OFC) over the last decade and highlights the latest innovations and understanding of the procedure.

Recent Findings

PRACTALL guidelines are widely used in OFC research, but there is still no international consensus on the OFC protocol in clinical practice. Guidelines for performing OFC in clinical practice have been updated to include oral food challenges for infants. There have been advances in predictive models for outcomes and severity of reaction during OFC that take into account multiple clinical data as well as newer laboratory modalities. Low-dose OFC and eliciting threshold dose determination are being examined for additional diagnostic and therapeutic use in the management of food allergy. Quality-of-life considerations have also been reviewed, as well as post-OFC assessment and care.

Summary

The OFC remains an important diagnostic tool in the management of food allergy and in clinical research. Advances in the field should improve safety and broaden the clinical applications of this essential procedure.

https://ift.tt/2SvqCJy

Letter to the Editor: In Response to Fang et al's Comment on “Diagnostic Accuracy of the McGill Thyroid Nodule Score in Pediatric Patients”

Clinical Endocrinology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2RjGQnM

Utility of systematic TSHR gene testing in adults with hyperthyroidism lacking overt autoimmunity and diffuse uptake on thyroid scintigraphy

Clinical Endocrinology, Volume 0, Issue ja, -Not available-.


https://ift.tt/2Przqle